DARATUMUMAB
Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Renal Cell Carcinoma (RCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Toripalimab Jinling Hospital, China | Phase 3 | BB |
Vorolanib Peking University Cancer Hospital & Institute | Phase 3 | B |
Abiraterone Acetate Exelixis | Phase 3 | B |
Tivantinib ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | B |
Epacadostat Incyte Corporation | Phase 3 | B |
View all 30 →
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →